CN Patent

CN102118972A — 鞘氨醇磷酸酯受体的新调节剂

Assigned to Scripps Research Institute · Expires 2011-07-06 · 15y expired

What this patent protects

本文提供了活化亚型1鞘氨醇-1-磷酸酯受体的化合物。某些化合物相对于亚型3鞘氨醇-1-磷酸酯受体选择性地活化亚型1受体。提供了本发明的化合物在治疗其中在医学上需要S1P1的活化、激动、抑制或拮抗的不良状况中的应用和方法。

USPTO Abstract

本文提供了活化亚型1鞘氨醇-1-磷酸酯受体的化合物。某些化合物相对于亚型3鞘氨醇-1-磷酸酯受体选择性地活化亚型1受体。提供了本发明的化合物在治疗其中在医学上需要S1P1的活化、激动、抑制或拮抗的不良状况中的应用和方法。

Drugs covered by this patent

ozanimod-hydrochloride (OZANIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: CN102118972A
Jurisdiction: CN
Classification: —
Expires: 2011-07-06
Drug substance claim: No
Drug product claim: No
Assignee: Scripps Research Institute
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.